Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Histiocytosis 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

selpercatinib 2pembrolizumab 2130-nm albumin-bound paclitaxel 2vandetanib 1trametinib 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1methyl N-acetylsibirosaminide 1lenvatinib 1fludarabine 1cemiplimab 1alectinib 1aldesleukin 1Thyrotropin Alfa 1Presenilin-1 1Panitumumab 1Interleukin-15 1Imatinib Mesylate 1IT-101 1IFL protocol 1Gemcitabine 1Dacarbazine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cetuximab 1Capecitabine 1Camptothecin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Neoplasms × Panitumumab × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡